Merck Outlines Strategic Shift Toward Clinical Trial Simplification and AI Integration
At the 2026 SCOPE Summit, Dr. Eliav Barr, Head of Global Clinical Development and Chief Medical Officer at Merck...
Moe Alsumidaie
Agentic AI for Clinical Trials: Medable’s Roadmap to Speed and Scale
In this in-depth Q&A, we sit with Andrew Mackinnon to explore Medable’s agentic AI platform and its first agents...
How Early-Stage Intelligence Determines Late-Stage Success
Why competitive insight in the earliest stages of developing a therapy can determine ultimate success By Alex Angelopoulos, Life...
The Seven-Day Miracle: Why the FDA’s New Pathway Could be the End of Randomized Clinical Trials
The parents of Baby K.J. (Kyle Patrick Muldoon, Jr.) didn’t have years to wait for a double-blind, placebo-controlled trial....
Korea’s Integrated Approach to Clinical Trial Planning: A New Model for Global Sponsors
The sponsor team had expected a slow start in Europe, but they weren’t prepared for how fragmented the process...
EMA Reports Near-Record 104 Medicine Approvals in 2025 with Strategic Focus on Cardiovascular Health
The European Medicines Agency (EMA) convened a comprehensive press briefing to dissect the regulatory milestones of 2025, a year...
Data Gluttony? Why Big Pharma is Addicted to 5.9 Million Useless Clinical Trial Datapoints
The lead site coordinator stared at the tablet, then at the patient, then back at the tablet. They were...
The QMSR Pivot: Navigating the New Quality Era for Clinical Trials
The date was February 2, 2024, but for the pharma executives and clinical trial specialists, it felt like the...
From Full Outsourcing to CRO-Agnostic Oversight: How UCB Is Rethinking Operating Models Under R3
At the Veeva Clinical Oversight Forum in Copenhagen, we spoke with David Appel, CSM Team Lead at UCB, and...
What R3 Really Means for Outsourcing Decisions at Novo Nordisk
At the Veeva Clinical Oversight Forum in Copenhagen, we spoke with Ibrahim Kamstrup-Akkaoui, VP of Business Architecture and Partnerships...